The Impact of COVID-19 on Pulmonary Procedures

February 11, 2026 updated by: M.D. Anderson Cancer Center

The Impact of COVID-19 on Pulmonary Procedures: A Nationwide Survey

This study investigates the changes in practice by pulmonary procedural programs across the United States as they faced the coronavirus pandemic. Information gathered from this study may help guide pulmonary programs on a wider scale and improve their practice. The study may also help researchers understand where they should focus research efforts to better respond to a pandemic in the future.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

PRIMARY OBJECTIVE:

I. To assess how pulmonary medicine programs adapted their procedural practices and techniques, ambulatory operations, and provider staffing in response to the coronavirus-2019 (COVID-19) epidemic.

OUTLINE:

Participants complete survey over 5-10 minutes.

Study Type

Observational

Enrollment (Estimated)

250

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • United States
    • Texas
      • Houston, Texas, United States, 77030
        • Recruiting
        • M D Anderson Cancer Center
        • Principal Investigator:
          • Bruce F. Sabath
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

Pulmonologists that are members of the American Association of Bronchology and Interventional Pulmonology (AABIP) and/or the American College of Chest Physicians (ACCP)

Description

Inclusion Criteria:

  • Pulmonologists that are members of the American Association of Bronchology and Interventional Pulmonology (AABIP) and/or the American College of Chest Physicians (ACCP)
  • These organizations were chosen because their member databases are composed of pulmonologists in the United States (U.S.) that perform the pulmonary procedures described in this survey. Letters of approval will be obtained from these organizations and provided to the MD Anderson Institutional Review Board (IRB). Once the MD Anderson IRB approves this survey study, the survey will be sent to the relevant subcommittees of these organizations for their electronic dissemination to their membership

Exclusion Criteria:

None

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Observational (survey)
Participants complete survey over 5-10 minutes.
Other: Survey Administration
Complete survey

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
To evaluate the pulmonary medicine programs adapted that their procedural practices in response to the coronavirus-2019 (COVID-19) epidemic.
Time Frame: through study completion, an average of 1 year
through study completion, an average of 1 year
To evaluate the pulmonary medicine programs that adapted their provider staffing in response to the coronavirus-2019 (COVID-19) epidemic.
Time Frame: through study completion, an average of 1 year
through study completion, an average of 1 year
To evaluate the pulmonary medicine programs that adapted their techniques in response to the coronavirus-2019 (COVID-19) epidemic.
Time Frame: through study completion, an average of 1 year
through study completion, an average of 1 year
To evaluate the pulmonary medicine programs that adapted their ambulatory operations in response to the coronavirus-2019 (COVID-19) epidemic.
Time Frame: through study completion, an average of 1 year
through study completion, an average of 1 year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

M.D. Anderson Cancer Center

Investigators

  • Principal Investigator: Bruce F Sabath, MD, M.D. Anderson Cancer Center

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 11, 2020

Primary Completion (Estimated)

February 2, 2027

Study Completion (Estimated)

February 2, 2027

Study Registration Dates

First Submitted

March 18, 2021

First Submitted That Met QC Criteria

August 24, 2021

First Posted (Actual)

August 26, 2021

Study Record Updates

Last Update Posted (Actual)

February 13, 2026

Last Update Submitted That Met QC Criteria

February 11, 2026

Last Verified

February 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2020-0662 (Other Identifier: M D Anderson Cancer Center)
  • NCI-2021-01788 (Registry Identifier: CTRP (Clinical Trial Reporting Program))

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Hematopoietic and Lymphoid Cell Neoplasm

Clinical Trials on Survey Administration

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Peru

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe